Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BioNTech SE    BNTX

BIONTECH SE

(BNTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
108.9(c) 105.45(c) 102.61(c) 105.85(c) 101.59 Last
4 772 780 3 560 296 1 816 018 1 910 243 3 146 667 Volume
+8.48% -3.17% -2.69% +3.16% -4.02% Change
More quotes
Financials
Sales 2020 497 M 600 M 600 M
Net income 2020 -329 M -398 M -398 M
Net cash position 2020 936 M 1 130 M 1 130 M
P/E ratio 2020 -77,2x
Yield 2020 -
Sales 2021 6 507 M 7 857 M 7 857 M
Net income 2021 4 445 M 5 368 M 5 368 M
Net cash position 2021 4 339 M 5 240 M 5 240 M
P/E ratio 2021 5,65x
Yield 2021 -
Capitalization 20 131 M 24 461 M 24 309 M
EV / Sales 2020 38,6x
EV / Sales 2021 2,43x
Nbr of Employees 1 800
Free-Float 92,4%
More Financials
Company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer... 
More about the company
Notations Surperformance© of BioNTech SE
Trading Rating : Investor Rating :
More Ratings
All news about BIONTECH SE
04:22pPFIZER : Vaccine Shortfall to Hit Europe, Canada as Pfizer Plant Is Upgraded
DJ
02:16pBIONTECH : Pfizer to Deliver 'Significantly' More COVID-19 Doses to Europe in Q2..
MT
01:02pBIONTECH : Statement on European Upscaling as well as Impact on Deliveries
PU
12:47pEUROPE : European stocks end four weeks of gains on lockdown, vaccine worries
RE
11:10aEuropean ADRs Move Sharply Lower in Friday Trading
MT
09:13aPFIZER : Temporarily Reduces Vaccine Deliveries to Europe to Upgrade Production ..
MT
07:43aETF PREVIEW : ETFs, Futures Point to Weaker Start as Slow Vaccine Rollout Weighs..
MT
04:46aBioNTech-Pfizer COVID-19 Vaccine May Get Japan Approval by Mid-February
MT
01/14PFIZER : Israel Vaccine Data Suggests Decrease in Covid-19 Infection Rate After ..
DJ
01/14UC Davis Health - New, more contagious strains of COVID-19 may be spreading q..
AQ
01/14Unilever gets vaccine partnership offers as it plots worker safety strategy
RE
01/14BioNTech, Pfizer Required to Conduct Indian Trial For COVID-19 Vaccine Before..
MT
01/14Philippines approves Pfizer-BioNTech vaccine for emergency use
RE
01/13SINOVAC BIOTECH : Philippines approves Pfizer-BioNTech vaccine for emergency use
RE
01/13Covid-19 Vaccine Distribution Changes Draw Concern at Local Level -- Update
DJ
More news
News in other languages on BIONTECH SE
04:18pMÄRKTE USA/Wall Street geht mit Verlusten ins Wochenende
04:11pWall Street conclut dans le rouge une semaine volatile
02:45pRetards de livraison du vaccin Pfizer, courroux des pays européens
01:52pBIONTECH : Nach kurzer Verringerung wird mehr Impfstoff geliefert
12:58pLieferverzögerungen bei Pfizer für Corona-Impfstoff - Sorge in Europa
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 92,59 €
Last Close Price 87,11 €
Spread / Highest target 27,5%
Spread / Average Target 6,28%
Spread / Lowest Target -33,9%
EPS Revisions
Managers and Directors
NameTitle
Ugur Sahin Chief Executive Officer
Helmut Jeggle Chairman-Supervisory Board
Sierk Pötting Chief Operating & Financial Officer
Özlem Türeci Chief Medical Officer
Christoph Huber Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BIONTECH SE24.62%25 487
GILEAD SCIENCES, INC.8.70%78 220
VERTEX PHARMACEUTICALS-4.57%58 800
REGENERON PHARMACEUTICALS7.21%54 663
WUXI APPTEC CO., LTD.3.52%53 415
BEIGENE, LTD.33.52%30 634